Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 21.38 GBp
Change Today 0.00 / 0.00%
Volume 1.0K
As of 11:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

allergy therapeutics plc (AGY) Snapshot

21.38 GBp
Previous Close
21.38 GBp
Day High
21.38 GBp
Day Low
21.38 GBp
52 Week High
02/17/15 - 26.75 GBp
52 Week Low
06/20/14 - 14.75 GBp
Market Cap
Average Volume 10 Days
0.0057 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

allergy therapeutics plc (AGY) Related Businessweek News

No Related Businessweek News Found

allergy therapeutics plc (AGY) Details

Allergy Therapeutics plc, a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical vaccine products for the immunological treatment of allergic conditions primarily in Europe. The company’s primary flagship product consists of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance, which enhances the immune response to an antigen or allergen. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzylpenicillin and related antibiotics (betalactams) by means of cutaneous tests (prick and intradermal). The company markets its products under various brands, including Pollinex Quattro, Polligoid, and TA Gräser Top. Allergy Therapeutics plc was founded in 1934 and is headquartered in Worthing, the United Kingdom.

345 Employees
Last Reported Date: 09/24/14
Founded in 1934

allergy therapeutics plc (AGY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 291.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 192.8K GBP
Compensation as of Fiscal Year 2014.

allergy therapeutics plc (AGY) Key Developments

Allergy Therapeutics plc Announces Unaudited Consolidated Earnings Report for the Six Months Ended December 31, 2014

Allergy Therapeutics plc announced unaudited consolidated earnings report for the six months ended December 31, 2014. For the period, the company reported revenue of £28,183,000 against £27,166,000 a year ago. Operating profit was £7,522,000 against £6,651,000 a year ago. Profit before tax was £7,413,000 against £6,523,000 a year ago. Profit for the period was £7,305,000 against £6,226,000 a year ago. Diluted earnings per share were 1.54 pence against 1.34 pence a year ago. Net cash generated by operating activities was £6,393,000 against £4,737,000 a year ago. Payments for property plant and equipment were £221,000 against £390,000 a year ago. Payments for intangible assets were £48,000.

Allergy Therapeutics plc to Report First Half, 2015 Results on Mar 02, 2015

Allergy Therapeutics plc announced that they will report first half, 2015 results on Mar 02, 2015

Allergy Therapeutics Provides Revenue Guidance for the First Half Ended December 31, 2014

Allergy Therapeutics provided revenue guidance for the first half ended December 31, 2014. The company expects to report revenue growth of 11% for the period at constant currency, with first half revenues of approximately £30.2 million compared to £27.2 million in first half of fiscal year 2014. This double digit sales growth has been driven primarily by the company's improving trading performance as it continues to increase its market share in all of its main markets. First half reported revenues are expected to be approximately £28.2 million compared to £27.2 million in first half of fiscal year 2014, representing growth of 4% taking into account currency impacts; the negative impact from the weakening Euro being £2.0 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGY:LN 21.38 GBp 0.00

AGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr823.00 DKK +2.00
DBV Technologies SA €44.52 EUR -0.76
Merck & Co Inc $59.38 USD -0.72
Sanofi €91.03 EUR -1.27
Stallergenes SA €56.32 EUR +0.48
View Industry Companies

Industry Analysis


Industry Average

Valuation AGY Industry Range
Price/Earnings 55.6x
Price/Sales 2.2x
Price/Book 4.5x
Price/Cash Flow 63.8x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGY THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at